Nano-Albumon (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nano-Albumon, is an albumin presented as a solution for injection for intravenous use. It is employed to treat hypoalbuminemia, volume depletion, severe burns and shock by expanding plasma volume in affected patients.

GNH USA supplies Nano-Albumon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to global markets. Customers benefit from reliable cold‑chain logistics and responsive technical support.

Nano-Albumon, a human serum albumin solution, acts as a plasma volume expander in conditions associated with low oncotic pressure, helping to restore circulatory homeostasis.

Hypoalbuminemia: restores plasma albumin levels and improves oncotic pressure. Volume depletion: expands intravascular volume to support circulatory stability. Severe burns: provides colloid support to counter fluid loss and edema. Shock: increases circulating volume to enhance tissue perfusion during acute circulatory failure. Post‑operative fluid management: assists in maintaining adequate plasma volume after major surgery.

Adverse reactions to Nano-Albumon may vary in frequency and severity.

Common Side Effects: - Fever: transient rise in body temperature after infusion. - Chills: shivering or feeling cold during or shortly after administration. - Headache: mild to moderate headache reported by some patients. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Volume overload: excessive fluid accumulation leading to pulmonary edema. - Hemolysis: destruction of red blood cells in rare cases. - Thrombosis: formation of blood clots in veins or arteries.

When using Nano-Albumon, clinicians should observe several precautionary measures to ensure patient safety. - Assess albumin levels: verify hypoalbuminemia before initiating therapy. - Monitor fluid balance: track input and output to avoid overload. - Evaluate cardiac function: use caution in patients with heart failure. - Screen for hypersensitivity: discontinue if signs of allergic reaction appear. - Adjust in renal impairment: consider reduced dosing in severe kidney disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nano-Albumon may interact with other medicines, altering fluid status or hemodynamic responses.

Major Interactions (Avoid): - High‑dose loop diuretics: concurrent use can precipitate profound volume depletion. - Other colloid solutions: combined administration may cause excessive plasma volume and overload. - Vasopressor agents: may require dose adjustments due to altered vascular tone.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor blood pressure for additive hypotensive effect. - Anticoagulants: albumin infusion can affect coagulation parameters; observe bleeding risk. - Radiographic contrast media: assess renal function as combined volume shifts may increase nephrotoxicity.